Consonance Capital Management’s Liminal BioSciences Inc. Common Shares LMNL Stock Holding History

Consonance Capital Management’s Portfolio LMNL Stock Details LMNL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-308,463	Closed	-$34.3M	–	45
2020 Q3	$34.3M	Sell	308,463 -20,268	-6%	-$2.74M	4.18%	11
2020 Q2	$35.4M	Hold	328,731	–	–	2.12%	19
2020 Q1	$22M	Hold	328,731	–	–	1.64%	23
2019 Q4	$27.5M	Buy	+328,731	New	+$22.2M	1.68%	23

Other funds holding LMNL

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Consonance Capital Management's LMNL Position: Q4 2020 in Review

Consonance Capital Management sold out of Liminal BioSciences Inc. Common Shares (LMNL) in Q4 2020, closing a stake of 308,463 shares — an estimated $34.3M sold.

Consonance Capital Management first reported a position in LMNL in Q4 2019 and held it in 4 quarters. The position peaked at $35.4M in Q2 2020. 16 funds tracked by Wall St. Rank hold LMNL as of Q4 2020.

Consonance Capital Management reported no remaining Liminal BioSciences Inc. Common Shares position as of Q4 2020 after selling out during the quarter.
Consonance Capital Management sold 308,463 Liminal BioSciences Inc. Common Shares shares in Q4 2020, an estimated $34.3M.
Consonance Capital Management first reported a position in Liminal BioSciences Inc. Common Shares in Q4 2019 and held it in 4 quarters.
Consonance Capital Management's Liminal BioSciences Inc. Common Shares position peaked at $35.4M in Q2 2020.
16 funds tracked by Wall St. Rank held Liminal BioSciences Inc. Common Shares as of Q4 2020.

Based on Consonance Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.